AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05869435 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FastWire System Device - Peripheral
Description: The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
Study NCT04447196 — intervention group
Intervention type: OTHER
Intervention: MDP
Description: Multi dimensional dyspnea profile scores at rest and during non invasive ventilation
Study NCT04962685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion
Description: Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months.
Study NCT05404750 — intervention group
Intervention type: BEHAVIORAL
Intervention: Harm Reduction
Description: Harm reduction aims to reduce negative effects of risky health behaviors without necessarily terminating the behaviors completely.Though often thought of as structural approaches (e.g., policy or syringe services), Harm reduction is also a relational approach to care focusing on non-punitive patient-provider interactions to promote autonomy. The degree to which harm reduction care is offered in study settings and is associated with clinical outcomes is the focus of this study.
Study NCT05357430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
Study NCT05357430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
Study NCT05357430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
Study NCT05399420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes
Study NCT04713891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 120 mg
Description: KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study NCT04713891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 240 mg
Description: KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study NCT04713891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 450 mg
Description: KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study NCT04713891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 tablets, 600 mg
Description: KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
Study NCT04713891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 (dosage RP2D-2) + Atezolizumab
Description: KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Study NCT04713891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 (dosage RP2D-1) + Atezolizumab
Description: KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Study NCT04713891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KF-0210 (dosage RP2D) + Atezolizumab
Description: KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
Study NCT06252948 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study (observational)
Description: Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
Study NCT06259552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Description: SPX- 303 Injection
Study NCT05462886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo INVSENSOR00057
Description: Noninvasive wearable health monitoring device
Study NCT06577285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc gluconate 50 mg with phytase supplement 176mg (800FTU)
Description: zinc gluconate 50 mg1 per day with phytase supplement 176mg (800FTU) (Goodphyte company) 2 tablets per day
Study NCT06577285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc gluconate 50 mg
Description: zinc gluconate 50 mg 1 per day, 4 days before botulinum toxin injections.
Study NCT05427604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Olive oil
Description: ingestion of olive oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
Study NCT05427604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Olive Oil
Description: ingestion of olive oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
Study NCT05427604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DHA oil
Description: ingestion of DHA oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
Study NCT05427604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DHA oil
Description: ingestion of DHA oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
Study NCT05563129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First aid lessons
Description: The school children will have first aid training
Study NCT06308848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota-Directed Food
Description: MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
Study NCT06308848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-Use Therapeutic Food
Description: RUTF is standard ready-to-use therapeutic food for SAM children aged 6 months and above.
Study NCT05670873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation given to the left dorsolateral prefrontal cortex
Study NCT05810454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPACES (interactive Physical and Cognitive Exercise System)
Description: iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations.
Study NCT05810454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PACE (Physical and Cognitive Exercise)
Description: PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations.
Study NCT06446544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VPFE monitoring with intraoperative alveolar recruitment maneuvers.
Description: VPFE monitoring with intraoperative alveolar recruitment maneuvers.
Study NCT06446544 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: VPFE monitoring with intraoperative alveolar recruitment maneuvers.
Description: VPFE monitoring with intraoperative alveolar recruitment maneuvers.
Study NCT05748223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness meditation has been reported to produce beneficial effects on a number of psychiatric, functional somatic, and stress-related symptoms and has therefore increasingly been incorporated into psychotherapeutic programs
Study NCT04092361 — intervention group
Intervention type: DEVICE
Intervention: optical coherence tomography
Description: It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
Study NCT06606483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDR-001
Description: Oral administration of small molecule MDR-001 tablets
Study NCT06606483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally placebo
Study NCT06589960 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Health education and physical exercise
Description: Nine face to face sessions and group discussion health education sessions. An Educational booklet was prepared and distributed to all attendants.~Lab results were discussed individually with each participant.~Rheumatologist and physiotherapist also provided messages.~The exercise program targeted and strengthened the muscles around the knee especially quadriceps muscle, stretching the muscles of lower limbs, and stretching and increasing the range of motion of front and back lower limb muscles (quadriceps muscle, hamstring muscle, gluteus muscle and calf muscles).~Phone calls to follow up the participants and maximize their adherence to the health education program. WhatsApp groups was created, and messages were distributed to summarize the content of the booklet and the exercises videos.~Final reassessment to assess the effect of health education and lifestyle modification was carried out with participants who continued till the end of the study.
Study NCT06611124 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: k -wires fixation for metacarpals fractures
Description: reduction and fixation of metacarpal fracture with k-wire
Study NCT06610253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Controlled, randomized, single-blind, parallel-group, prospective. Planned, parallel, randomized, single-blind, controlled clinical trial (RCT). Participants will be randomly assigned to one of four interventions: Whey Protein Concentrate - WPC, Pea Protein Isolate - PPI, Rice Protein ISOLATE - RPI, a combination of PPI and RPI to see if the intervention works together in synergy.~The experiment was scheduled for week 8. Each participant will consume 30g of a dedicated preparation every day for 8 weeks. The planned measurements will be performed three times - before the experiment begins, after 4 and 8 weeks.
Study NCT06610253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Controlled, randomized, single-blind, parallel-group, prospective. Planned, parallel, randomized, single-blind, controlled clinical trial (RCT). Participants will be randomly assigned to one of four interventions: Whey Protein Concentrate - WPC, Pea Protein Isolate - PPI, Rice Protein ISOLATE - RPI, a combination of PPI and RPI to see if the intervention works together in synergy.~The experiment was scheduled for week 8. Each participant will consume 30g of a dedicated preparation every day for 8 weeks. The planned measurements will be performed three times - before the experiment begins, after 4 and 8 weeks.
Study NCT06610812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KETOGENIC MEDITERRANEAN diet
Description: each patient in group A was instructed briefly about the nature of the treatment regimen to gain the patient's confidence and cooperation. the patient will receive ketogenic Mediterranean diet with aerobic training program. The diet will contain approximately 9300 kJ accordingly, 37% as total fat, 18% as monounsaturated and 9% as saturated, and 33 g of fiber per day for 3 months with moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.~This procedure performed by using the components of ketogenic Mediterranean diet:~* Protein source: fatty fish, seafood, poultry, and eggs.~* Fats and oils: olive oil, avocado oil, and MCT oil (medium-chain triglycerides oil).~* Low carb vegetables: leafy greens, cruciferous vegetables, and other low carb veggies.~* Low carb fruits: avocados, olives, and tomato.~* Flavourings: paprika, cumin, cinnamon, coriander, anise, lemon or lime juice , mint , parsley and garlic .
Study NCT06610812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypo-caloric diet:
Description: Group (b) received low caloric balanced diet regimen with aerobic exercise for 3 months in the form of moderate aerobic exercises in the form of walking for 30 to 45 minutes a day, 3 times per week for 3 months. This group received a diet of 1800 calories or lower accordingly including a combination of two or more of the following in each meal: Non starchy vegetable: spinach, broccoli, cauliflower, peppers, mushrooms, tomatoes, etc.~Fruits: berries, apples bears, citrus fruits, melon, grapes bananas, etc. Starchy vegetables: potatoes peas, sweet potatoes etc. Fish and shellfish: salmon, clams, Trouts, oysters, etc. Eggs: whole eggs are more nutrient dense than white eggs. Poultry and meat: chicken turkey, beef, lamb, etc. Whole grains: oats, brown rice, farro etc. Legumes: chickpeas, kidney beans, lentils etc. Healthy fats: avocados, olive oil, unsweetened coconut, avocado oil. Dairy products: full-fat or reduced fat plain yogurt kefir and full-fat cheese.
Study NCT06610812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate aerobic exercises
Description: moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.
Study NCT06610435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Various soft tissue and joint mobilizations, intramuscular stretches, trigger point treatments, and intraoral applications for the temporomandibular joint were performed in 15 randomly selected bruxism patients. Soft tissue mobilization techniques were applied bilaterally on the trigger points in the masseter, temporal, lateral and medial pterygoid muscles of the masticatory muscles in the transverse direction from inside and outside the mouth. In addition, deep friction massage and myofascial relaxation techniques were applied to suprahyoid and infrahyoid muscles, sternocleidomastoid, scalene, upper trapezius, levator scapula and suboccipital muscles until relaxation was felt. In addition, distraction and bridging techniques were applied in the suboccipital region to release the tissue and fascia techniques were applied in the cervical region to loosen the fascia. The manual therapy procedure, which was applied in the supine position and lasted approximately 40 minutes for 8 weeks
Study NCT06610435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: The exercise group consisted of 15 randomly selected bruxist individuals and aimed to reduce pain, decrease involuntary contractions of masticatory muscles, increase their nutrition, flexibility and coordination, and strengthen weak muscles with exercise therapy. These exercises consist of resistant isometric jaw movements to increase coordination and relaxation of the masticatory muscles (post isometric relaxation technique), Rocabado exercises, stretching and posture exercises for temporal, masseter and suprahyoid muscles as well as neck muscles. All individuals in this group were taught the programmed exercises practically and were asked to repeat the home exercises (lasting approximately 25 minutes) three times a week for 8 weeks. In addition, a video explaining the exercises in detail was shared with all participants in the group in order to ensure that the exercises were not forgotten and to achieve accuracy and standardization among the participants.
Study NCT06610500 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires investigating the prescription and dispensing of clozapine.
Study NCT06610149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Description: 8 weeks treatment with Probiotic mixture
Study NCT06609811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal Influenza Live Attenuated Vaccine
Description: This vaccine is produced by Changchun BCHT Biotechnology Co.
Study NCT06610383 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical extraction of wisdom teeth in the morning
Description: The patients in this group underwent impacted tooth surgery at 08:30 in the morning.
Study NCT06610383 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical extraction of wisdom teeth in the afternoon
Description: Impacted tooth surgery was performed on the patients in this group at 15:30.
Study NCT06440135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Taken orally once per day
Study NCT06189638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Description: Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
Study NCT06189638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Description: Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
Study NCT06357325 — intervention group
Intervention type: OTHER
Intervention: a qualitative study.
Description: Before the interview process began, an interview form was created in accordance with the study design. In the study, care was taken to use open-ended general questions that would allow the participant to provide detailed information on the subject and did not require short answers such as short and clear questions, multiple choice questions, and yes-no questions.~For the analysis and reporting phase, an introduction was made in the form of a conversation with the participant before starting the interview, and then the interview was started if the participant was available. During the transcription phase, the questions were asked during the interview in such a way as to allow the participant to express themselves in detail without any direction or comment. The interview was conducted individually by calling each woman by telephone. During the interview, the researcher transcribed the interviewee's sentences exactly as she expressed them.
Study NCT06166056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6333
Description: CHF6333 Part I SAD; CHF6333 Part II MD.
Study NCT06166056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF6333 Placebo
Description: Placebo Part I SAD; Placebo Part II MD.
Study NCT05242029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo in a clinical setting.
Study NCT05242029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo in a clinical setting.
Study NCT05762289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (in weight bearing and non weight bearing)
Description: Pain and Range of cervical motion was assessed before and after manipulation in both groups.
Study NCT05762289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thrust Manipulation (in weight bearing and non weight bearing)
Description: Pain and Range of cervical motion was assessed before and after manipulation in both groups.